SAB Biotherapeutics, Inc. (SABS) stock
SABSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.96−0.12 (-3.90%)
Close on Nov 13, 2026Market cap $269.32MP/E –Yield –
SAB Biotherapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
SAB Biotherapeutics's enterprise value was $157.03M on Nov 11, 2026, against $76.72M a year earlier. Over the last 5 years it ranged from -$19.69M to $341.10M, with a median of $50.39M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $157.03M | +135.3% |
| 2025 | Dec 31, 2025 | $66.75M | +1345.7% |
| 2024 | Dec 31, 2024 | $4.62M | -92.4% |
| 2023 | Dec 29, 2023 | $61.05M | +67.4% |
| 2022 | Dec 30, 2022 | $36.46M | +5.3% |
| 2021 | Dec 31, 2021 | $34.62M | – |
See a number that looks wrong?